Skip to main content
  • Dupixent
  • Advancing to a Biologic

Oral Presentations

Abstract Submission is now closed. Below please find the list of late-breaking research oral presentations that will take place on Monday, December 13, 2021.


• 8:00 AM EST - #584: Short-Term Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis Stratified by Age

• 8:08 AM EST - #632: Epidemiology and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort

• 8:16 AM EST - #648: Elevated C-reactive protein levels in atopic dermatitis patients with sleep disturbance is associated with the development of cardiovascular comorbidities and increased mortality: a multi-center cohort study

• 8:24 AM EST - #663: Efficacy and Safety of Dupilumab in Children Aged 6–11 Years with Inadequately Controlled Severe Atopic Dermatitis: Results From an Open-Label Extension Trial up to 1 Year

• 8:32 AM EST - #664: Achieving a Deep Response on Patient-Reported Outcomes with Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Phase 3 Trials

• 8:40 AM EST - #666: Patient Preferences for Features of Systemic Atopic Dermatitis Therapies: A Discrete-Choice Experiment Study

• 8:48 AM EST - #680: Identifying Patient Subgroups With Comparable Benefit From Continuous Versus Reduced Abrocitinib Maintenance Doses in JADE REGIMEN

• 8:56 AM EST - #681: Onset and Depth of Response with Abrocitinib Versus Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: Analysis of the Phase 3b JADE DARE Clinical Trial

• 9:04 AM EST - #684: Efficacy of Abrocitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals

• 9:12 AM EST - #686: Development of an Eczema Area and Severity Index (EASI) lesional severity atlas for diverse skin types

• 9:20 AM EST - #688: Associations between shower and moisturizing practices with atopic dermatitis severity: a prospective observational study

• 9:28 AM - EST #690: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 Months to 6 Years With Moderate-to-Severe Atopic Dermatitis